Solvay Pharmaceuticals, Gmbh

Abbott Products Gmbh

Solvay Pharmaceutical Gmbh

Peter-Colin Gregory

Jochen Antel

Harald Waldeck

Michael Firnges

Dania B Reiche

Uwe Schoen

Michael Wurl

Josephus Hubertus Maria Lange

Holger Sann

Bernd Thumbeck

George Shlieout

Bernd Boedecker

Andreas Potthoff

Siegfried Schaefer

Uwe Reinecker

Maike Wolff

Sabine Irmer

Dania Reiche

Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.

Pharmaceutical compositions of lipase-containing products, in particular of pancreation

Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one Kchannel opener as a first active agent and at least one CBcannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined Kchannel opening and CBantagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising Kchannel openers and CBantagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined Kchannel opening and CBantagonistic properties.

Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions. 

N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions

Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a Kchannel modulator; and (ii) a CBmodulator. Also described herein are methods of making and using these compositions.

Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

N-sulfamoyl-N'-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions 

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

Novel and known trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds for the treatment and/or inhibition of obesity and of concomitant and/or secondary diseases involved therewith, in particular metabolic syndrome and cardiovascular diseases. Novel trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds, pharmaceutical preparations containing them and processes for the preparation of these compounds. Also compounds acting as inhibitors of lipase, in particular pancreatic lipase.

Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment

Growing community of inventors

Hannover, Germany

Peter-Colin Gregory